CD33 and acute myeloid leukemia: The first report on the use of CLL1-CAR in an AML pediatric patient was by Liu et al. Compound CAR-T targeting CLL1 and CD33 was constructed, and alemtuzumab was administered with the goal of clearing CAR-T-cells after tumor eradiation.